Literature DB >> 17038272

The management of atrial fibrillation in heart failure.

Rupa Bala1, David J Callans.   

Abstract

The development of atrial fibrillation (AF) can greatly complicate the course of heart failure (HF). Although recent trials have indicated the nonsuperiority of a rhythm control strategy in the general population with AF, this may not apply to patients with HF. We feel strongly that AF be treated aggressively in patients with HF, defaulting toward an initial rhythm control strategy, to avoid the hemodynamic detriment of irregular rapid ventricular response and the development of tachycardia-related myopathy. The index episode is treated with cardioversion and antiarrhythmic therapy. If significant benefit is demonstrated, the rhythm control strategy is maintained, to the point of catheter ablation for AF if necessary. If there is no change in cardiac performance or symptoms after cardioversion, strict rate control is enforced, to the point of atrioventricular node ablation and pacing if necessary.

Entities:  

Year:  2006        PMID: 17038272     DOI: 10.1007/s11936-006-0053-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  35 in total

1.  Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis.

Authors:  M A Wood; C Brown-Mahoney; G N Kay; K A Ellenbogen
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

2.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

Review 3.  Mechanisms of atrial remodeling and clinical relevance.

Authors:  Stanley Nattel; Akiko Shiroshita-Takeshita; Sophie Cardin; Patricia Pelletier
Journal:  Curr Opin Cardiol       Date:  2005-01       Impact factor: 2.161

Review 4.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

Authors:  William H Maisel; Lynne Warner Stevenson
Journal:  Am J Cardiol       Date:  2003-03-20       Impact factor: 2.778

Review 5.  Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets.

Authors:  Joachim R Ehrlich; Stanley Nattel; Stefan H Hohnloser
Journal:  J Cardiovasc Electrophysiol       Date:  2002-04

6.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.

Authors:  O D Pedersen; H Bagger; L Kober; C Torp-Pedersen
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

7.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

8.  Catheter ablation for atrial fibrillation in congestive heart failure.

Authors:  Li-Fern Hsu; Pierre Jaïs; Prashanthan Sanders; Stéphane Garrigue; Mélèze Hocini; Fréderic Sacher; Yoshihide Takahashi; Martin Rotter; Jean-Luc Pasquié; Christophe Scavée; Pierre Bordachar; Jacques Clémenty; Michel Haïssaguerre
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

9.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

10.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.

Authors:  D L Dries; D V Exner; B J Gersh; M J Domanski; M A Waclawiw; L W Stevenson
Journal:  J Am Coll Cardiol       Date:  1998-09       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.